HFS
RCUS icon

Hantz Financial Services’s Arcus Biosciences RCUS Stock Holding History

Hantz Financial Services’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38K Buy
1,757
+153
+10% +$3.3K ﹤0.01% 1653
2025
Q4 		$38K Buy
1,604
+881
+122% +$18K ﹤0.01% 1545
2025
Q3 		$10K Buy
723
+440
+155% +$4.58K ﹤0.01% 1838
2025
Q2 		$2K Buy
283
+272
+2,473% +$2.32K ﹤0.01% 2016
2025
Q1 		$0 Buy
+11
New +$128 ﹤0.01% 1922

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Hantz Financial Services's RCUS Position: Q1 2026 in Review

Hantz Financial Services increased its Arcus Biosciences (RCUS) stake by 9.5% in Q1 2026, buying an estimated $3.3K and bringing the position to 1,757 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

Hantz Financial Services first reported a position in RCUS in Q1 2025 and has held it in 5 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Hantz Financial Services held 1,757 shares of Arcus Biosciences worth $38K as of Q1 2026.
  • Hantz Financial Services bought 153 Arcus Biosciences shares in Q1 2026, an estimated $3.3K.
  • Arcus Biosciences made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #1653 holding.
  • Hantz Financial Services first reported a position in Arcus Biosciences in Q1 2025 and has held it in 5 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.